RXST
RxSight, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$4.69
+3.99%Year over year
Reported trailing growth
- Revenue
- -18.8%
- EBITDA
- -49.6%
- EBIT
- -29.6%
- EPS
- -41.2%
- Free cash flow
- -30.6%
- Operating cash flow
- -35.8%
Forward estimates
Based on analyst estimates
- Revenue
- +29.3%
- EBITDA
- +32.2%
- EPS
- +26.7%
Three-year CAGR
- Revenue
- +40.0%
- EBITDA
- -49.7%
- EBIT
- -30.7%
- Net income
- -41.8%
- EPS
- -33.8%
- Free cash flow
- +13.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026